Bupropion for the treatment of apathy in Alzheimer disease a randomized clinical trial

This randomized clinical trial examines the efficacy and safety of the dopamine and noradrenaline reuptake inhibitor bupropion in the treatment of apathy in patients with dementia of Alzheimer type. Importance Apathy is a frequent neuropsychiatric symptom in dementia of Alzheimer type and negatively...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Maier, Franziska (VerfasserIn) , Spottke, Annika (VerfasserIn) , Bach, Jan-Philipp (VerfasserIn) , Bartels, Claudia (VerfasserIn) , Buerger, Katharina (VerfasserIn) , Dodel, Richard (VerfasserIn) , Fellgiebel, Andreas (VerfasserIn) , Fliessbach, Klaus (VerfasserIn) , Frölich, Lutz (VerfasserIn) , Hausner, Lucrezia (VerfasserIn) , Hellmich, Martin (VerfasserIn) , Kloeppel, Stefan (VerfasserIn) , Klostermann, Arne (VerfasserIn) , Kornhuber, Johannes (VerfasserIn) , Laske, Christoph (VerfasserIn) , Peters, Oliver (VerfasserIn) , Priller, Josef (VerfasserIn) , Richter-Schmidinger, Tanja (VerfasserIn) , Schneider, Anja (VerfasserIn) , Shah-Hosseini, Kija (VerfasserIn) , Teipel, Stefan (VerfasserIn) , von Arnim, Christine A. F. (VerfasserIn) , Wiltfang, Jens (VerfasserIn) , Jessen, Frank (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: May 28, 2020
In: JAMA network open
Year: 2020, Jahrgang: 3, Heft: 5
ISSN:2574-3805
Online-Zugang: Volltext
Verfasserangaben:Franziska Maier, Annika Spottke, Jan-Philipp Bach, Claudia Bartels, Katharina Buerger, Richard Dodel, Andreas Fellgiebel, Klaus Fliessbach, Lutz Froelich, Lucrezia Hausner, Martin Hellmich, Stefan Kloeppel, Arne Klostermann, Johannes Kornhuber, Christoph Laske, Oliver Peters, Josef Priller, Tanja Richter-Schmidinger, Anja Schneider, Kija Shah-Hosseini, Stefan Teipel, Christine A. F. von Arnim, Jens Wiltfang, Frank Jessen

MARC

LEADER 00000caa a2200000 c 4500
001 1737535963
003 DE-627
005 20230426153230.0
007 cr uuu---uuuuu
008 201102s2020 xx |||||o 00| ||eng c
024 7 |a 10.1001/jamanetworkopen.2020.6027  |2 doi 
035 |a (DE-627)1737535963 
035 |a (DE-599)KXP1737535963 
035 |a (OCoLC)1341375372 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Maier, Franziska  |d 1982-  |e VerfasserIn  |0 (DE-588)104781207X  |0 (DE-627)779251636  |0 (DE-576)401625915  |4 aut 
245 1 0 |a Bupropion for the treatment of apathy in Alzheimer disease a randomized clinical trial  |c Franziska Maier, Annika Spottke, Jan-Philipp Bach, Claudia Bartels, Katharina Buerger, Richard Dodel, Andreas Fellgiebel, Klaus Fliessbach, Lutz Froelich, Lucrezia Hausner, Martin Hellmich, Stefan Kloeppel, Arne Klostermann, Johannes Kornhuber, Christoph Laske, Oliver Peters, Josef Priller, Tanja Richter-Schmidinger, Anja Schneider, Kija Shah-Hosseini, Stefan Teipel, Christine A. F. von Arnim, Jens Wiltfang, Frank Jessen 
264 1 |c May 28, 2020 
300 |a 14 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 02.11.2020 
520 |a This randomized clinical trial examines the efficacy and safety of the dopamine and noradrenaline reuptake inhibitor bupropion in the treatment of apathy in patients with dementia of Alzheimer type. Importance Apathy is a frequent neuropsychiatric symptom in dementia of Alzheimer type and negatively affects the disease course and patients' and caregivers' quality of life. Effective treatment options are needed. Objective To examine the efficacy and safety of the dopamine and noradrenaline reuptake inhibitor bupropion in the treatment of apathy in patients with dementia of Alzheimer type. Design, Setting, and Participants This 12-week, multicenter, double-blind, placebo-controlled, randomized clinical trial was conducted in a psychiatric and neurological outpatient setting between July 2010 and July 2014 in Germany. Patients with mild-to-moderate dementia of Alzheimer type and clinically relevant apathy were included. Patients with additional clinically relevant depressed mood were excluded. Data analyses were performed between August 2018 and August 2019. Interventions Patients received either bupropion or placebo (150 mg for 4 weeks plus 300 mg for 8 weeks). In case of intolerability of 300 mg, patients continued to receive 150 mg throughout the study. Main Outcomes and Measures Change on the Apathy Evaluation Scale-Clinician Version (AES-C) (score range, 18-72 points) between baseline and week 12 was the primary outcome parameter. Secondary outcome parameters included measures of neuropsychiatric symptoms, cognition, activities of daily living, and quality of life. Outcome measures were assessed at baseline and at 4, 8, and 12 weeks. Results A total of 108 patients (mean [SD] age, 74.8 [5.9] years; 67 men [62%]) were included in the intention-to-treat analysis, with 54 randomized to receive bupropion and 54 randomized to receive placebo. The baseline AES-C score was comparable between the bupropion group and the placebo group (mean [SD], 52.2 [8.7] vs 50.4 [8.2]). After controlling for the baseline AES-C score, site, and comedication with donepezil or galantamine, the mean change in the AES-C score between the bupropion and placebo groups was not statistically significant (mean change, 2.22; 95% CI, -0.47 to 4.91; P = .11). Results on secondary outcomes showed statistically significant differences between bupropion and placebo in terms of total neuropsychiatric symptoms (mean change, 5.52; 95% CI, 2.00 to 9.04; P = .003) and health-related quality of life (uncorrected for multiple comparisons; mean change, -1.66; 95% CI, -3.01 to -0.31; P = .02) with greater improvement in the placebo group. No statistically significant changes between groups were found for activities of daily living (mean change, -2.92; 95% CI, -5.89 to 0.06; P = .05) and cognition (mean change, -0.27; 95% CI, -3.26 to 2.73; P = .86). The numbers of adverse events (bupropion group, 39 patients [72.2%]; placebo group, 33 patients [61.1%]) and serious adverse events (bupropion group, 5 patients [9.3%]; placebo group, 2 patients [3.7%]) were comparable between groups. Conclusions and Relevance Although it is safe, bupropion was not superior to placebo for the treatment of apathy in patients with dementia of Alzheimer type in the absence of clinically relevant depressed mood. Question Is bupropion an effective and safe treatment for apathy in nondepressed patients with dementia of Alzheimer type? Findings In this 12-week, multicenter, double-blind, placebo-controlled, randomized clinical trial, 54 patients received bupropion and 54 received placebo. The mean change in the Apathy Evaluation Scale-Clinician Version score was not statistically significant between the treatment groups. Meaning Bupropion did not improve apathy in patients with dementia of Alzheimer type without depressed mood. 
650 4 |a cognitive impairment 
650 4 |a dementia 
650 4 |a depression 
650 4 |a dopamine 
650 4 |a double-blind 
650 4 |a methylphenidate 
650 4 |a multidimensional apathy 
650 4 |a neuropsychiatric symptoms 
650 4 |a prevalence 
700 1 |a Spottke, Annika  |e VerfasserIn  |4 aut 
700 1 |a Bach, Jan-Philipp  |e VerfasserIn  |4 aut 
700 1 |a Bartels, Claudia  |e VerfasserIn  |4 aut 
700 1 |a Buerger, Katharina  |e VerfasserIn  |4 aut 
700 1 |a Dodel, Richard  |e VerfasserIn  |4 aut 
700 1 |a Fellgiebel, Andreas  |e VerfasserIn  |4 aut 
700 1 |a Fliessbach, Klaus  |e VerfasserIn  |4 aut 
700 1 |a Frölich, Lutz  |d 1956-  |e VerfasserIn  |0 (DE-588)1028327099  |0 (DE-627)730567516  |0 (DE-576)375813160  |4 aut 
700 1 |a Hausner, Lucrezia  |d 1980-  |e VerfasserIn  |0 (DE-588)138821364  |0 (DE-627)606151257  |0 (DE-576)309247020  |4 aut 
700 1 |a Hellmich, Martin  |e VerfasserIn  |4 aut 
700 1 |a Kloeppel, Stefan  |e VerfasserIn  |4 aut 
700 1 |a Klostermann, Arne  |e VerfasserIn  |4 aut 
700 1 |a Kornhuber, Johannes  |e VerfasserIn  |4 aut 
700 1 |a Laske, Christoph  |e VerfasserIn  |4 aut 
700 1 |a Peters, Oliver  |e VerfasserIn  |4 aut 
700 1 |a Priller, Josef  |e VerfasserIn  |4 aut 
700 1 |a Richter-Schmidinger, Tanja  |e VerfasserIn  |4 aut 
700 1 |a Schneider, Anja  |e VerfasserIn  |4 aut 
700 1 |a Shah-Hosseini, Kija  |e VerfasserIn  |4 aut 
700 1 |a Teipel, Stefan  |e VerfasserIn  |4 aut 
700 1 |a von Arnim, Christine A. F.  |e VerfasserIn  |4 aut 
700 1 |a Wiltfang, Jens  |e VerfasserIn  |4 aut 
700 1 |a Jessen, Frank  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t JAMA network open  |d Chicago, Ill. : American Medical Association, 2018  |g 3(2020,5) Artikel-Nummer e206027, 14 Seiten  |h Online-Ressource  |w (DE-627)1023451867  |w (DE-600)2931249-8  |w (DE-576)505831112  |x 2574-3805  |7 nnas  |a Bupropion for the treatment of apathy in Alzheimer disease a randomized clinical trial 
773 1 8 |g volume:3  |g year:2020  |g number:5  |g extent:14  |a Bupropion for the treatment of apathy in Alzheimer disease a randomized clinical trial 
951 |a AR 
992 |a 20201102 
993 |a Article 
994 |a 2020 
998 |g 138821364  |a Hausner, Lucrezia  |m 138821364:Hausner, Lucrezia  |d 60000  |e 60000PH138821364  |k 0/60000/  |p 10 
998 |g 1028327099  |a Frölich, Lutz  |m 1028327099:Frölich, Lutz  |d 60000  |e 60000PF1028327099  |k 0/60000/  |p 9 
999 |a KXP-PPN1737535963  |e 3790800716 
BIB |a Y 
SER |a journal 
JSO |a {"title":[{"title_sort":"Bupropion for the treatment of apathy in Alzheimer disease a randomized clinical trial","title":"Bupropion for the treatment of apathy in Alzheimer disease a randomized clinical trial"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"14 S."}],"id":{"eki":["1737535963"],"doi":["10.1001/jamanetworkopen.2020.6027"]},"relHost":[{"name":{"displayForm":["American Medical Association"]},"recId":"1023451867","title":[{"title":"JAMA network open","title_sort":"JAMA network open"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["2574-3805"],"eki":["1023451867"],"zdb":["2931249-8"]},"origin":[{"publisherPlace":"Chicago, Ill.","dateIssuedDisp":"[2018]-","publisher":"American Medical Association"}],"language":["eng"],"part":{"text":"3(2020,5) Artikel-Nummer e206027, 14 Seiten","extent":"14","issue":"5","volume":"3","year":"2020"},"pubHistory":["Vol 1, no. 1 (May 2018)-"],"disp":"Bupropion for the treatment of apathy in Alzheimer disease a randomized clinical trialJAMA network open","type":{"media":"Online-Ressource","bibl":"periodical"}}],"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"May 28, 2020"}],"language":["eng"],"name":{"displayForm":["Franziska Maier, Annika Spottke, Jan-Philipp Bach, Claudia Bartels, Katharina Buerger, Richard Dodel, Andreas Fellgiebel, Klaus Fliessbach, Lutz Froelich, Lucrezia Hausner, Martin Hellmich, Stefan Kloeppel, Arne Klostermann, Johannes Kornhuber, Christoph Laske, Oliver Peters, Josef Priller, Tanja Richter-Schmidinger, Anja Schneider, Kija Shah-Hosseini, Stefan Teipel, Christine A. F. von Arnim, Jens Wiltfang, Frank Jessen"]},"recId":"1737535963","person":[{"given":"Franziska","display":"Maier, Franziska","family":"Maier","role":"aut"},{"role":"aut","family":"Spottke","given":"Annika","display":"Spottke, Annika"},{"display":"Bach, Jan-Philipp","given":"Jan-Philipp","family":"Bach","role":"aut"},{"family":"Bartels","role":"aut","given":"Claudia","display":"Bartels, Claudia"},{"family":"Buerger","role":"aut","given":"Katharina","display":"Buerger, Katharina"},{"given":"Richard","display":"Dodel, Richard","role":"aut","family":"Dodel"},{"display":"Fellgiebel, Andreas","given":"Andreas","family":"Fellgiebel","role":"aut"},{"given":"Klaus","display":"Fliessbach, Klaus","family":"Fliessbach","role":"aut"},{"given":"Lutz","display":"Frölich, Lutz","role":"aut","family":"Frölich"},{"family":"Hausner","role":"aut","given":"Lucrezia","display":"Hausner, Lucrezia"},{"role":"aut","family":"Hellmich","display":"Hellmich, Martin","given":"Martin"},{"family":"Kloeppel","role":"aut","display":"Kloeppel, Stefan","given":"Stefan"},{"display":"Klostermann, Arne","given":"Arne","family":"Klostermann","role":"aut"},{"given":"Johannes","display":"Kornhuber, Johannes","role":"aut","family":"Kornhuber"},{"role":"aut","family":"Laske","given":"Christoph","display":"Laske, Christoph"},{"given":"Oliver","display":"Peters, Oliver","role":"aut","family":"Peters"},{"role":"aut","family":"Priller","display":"Priller, Josef","given":"Josef"},{"given":"Tanja","display":"Richter-Schmidinger, Tanja","role":"aut","family":"Richter-Schmidinger"},{"family":"Schneider","role":"aut","given":"Anja","display":"Schneider, Anja"},{"given":"Kija","display":"Shah-Hosseini, Kija","role":"aut","family":"Shah-Hosseini"},{"family":"Teipel","role":"aut","given":"Stefan","display":"Teipel, Stefan"},{"given":"Christine A. F.","display":"von Arnim, Christine A. F.","family":"von Arnim","role":"aut"},{"role":"aut","family":"Wiltfang","display":"Wiltfang, Jens","given":"Jens"},{"family":"Jessen","role":"aut","display":"Jessen, Frank","given":"Frank"}],"note":["Gesehen am 02.11.2020"]} 
SRT |a MAIERFRANZBUPROPIONF2820